Genome-wide association study of cardiac troponin i in the general population
Moksnes, Marta Riise; Røsjø, Helge; Richmond, Anne; Lyngbakken, Magnus N; Graham, Sarah E; Wolford, Brooke N; Hansen, Ailin Falkmo; Gagliano Taliun, Sarah A; Lefaive, Jonathon; Rasheed, Humaira; Thomas, Laurent; Zhou, Wei; Aung, Nay; Surakka, Ida; Douville, Nicholas J; Campbell, Archie; Porteous, David J; Petersen, Steffen E; Munroe, Patricia B; Welsh, Paul; Sattar, Naveed; Smith, George Davey; Fritsche, Lars G; Nielsen, Jonas Bille; Åsvold, Bjørn Olav; Hveem, Kristian; Hayward, Caroline; Willer, Cristen J; Brumpton, Ben M; Omland, Torbjørn
Peer reviewed, Journal article
MetadataShow full item record
Original versionHuman Molecular Genetics. 2021, 30 (21), 2027-2039. 10.1093/hmg/ddab124
Circulating cardiac troponin proteins are associated with structural heart disease and predict incident cardiovascular disease in the general population. However, the genetic contribution to cardiac troponin I (cTnI) concentrations and its causal effect on cardiovascular phenotypes are unclear. We combine data from two large population-based studies, the Trøndelag Health Study and the Generation Scotland Scottish Family Health Study, and perform a genome-wide association study of high-sensitivity cTnI concentrations with 48 115 individuals. We further use two-sample Mendelian randomization to investigate the causal effects of circulating cTnI on acute myocardial infarction (AMI) and heart failure (HF). We identified 12 genetic loci (8 novel) associated with cTnI concentrations. Associated protein-altering variants highlighted putative functional genes: CAND2, HABP2, ANO5, APOH, FHOD3, TNFAIP2, KLKB1 and LMAN1. Phenome-wide association tests in 1688 phecodes and 83 continuous traits in UK Biobank showed associations between a genetic risk score for cTnI and cardiac arrhythmias, metabolic and anthropometric measures. Using two-sample Mendelian randomization, we confirmed the non-causal role of cTnI in AMI (5948 cases, 355 246 controls). We found indications for a causal role of cTnI in HF (47 309 cases and 930 014 controls), but this was not supported by secondary analyses using left ventricular mass as outcome (18 257 individuals). Our findings clarify the biology underlying the heritable contribution to circulating cTnI and support cTnI as a non-causal biomarker for AMI in the general population. Using genetically informed methods for causal inference helps inform the role and value of measuring cTnI in the general population.